Brief: Alpha Cognition Announces FDA Acceptance Of New Drug Application For Mild-To-Moderate Alzheimer’S Disease
07/12/2023 21:49
Dec 7 (Reuters) - Alpha Cognition Inc ACOG.CD :
* ALPHA COGNITION ANNOUNCES FDA ACCEPTANCE OF NEW DRUG
APPLICATION
FOR ALPHA-1062 FOR MILD-TO-MODERATE ALZHEIMER’S DISEASE
* ALPHA COGNITION INC: NDA HAS BEEN GRANTED A PRESCRIPTION
DRUG
USER FEE ACT GOAL DATE OF JULY 27TH, 2024
Source text for Eikon: ID:nBw1yNxjJa
Further company coverage: ACOG.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Cognition
See all newsBrief: Alpha Cognition Announces Pricing Of $50 Million Upsized Public Offering And Nasdaq Listing
Brief: Alpha Cognition Inc - Files Registration Statement For $25 Million Offering
Brief: Alpha Cognition Announces Completion Of $4.545 Million Convertible Note And Warrants Bridge Financing
Brief: Alpha Cognition Says On Track To Secure Financing For Continued Growth
Brief: Alpha Cognition Inc Says Applied To List Common Shares On Nasdaq Under Trading Symbol “Acog”